The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Glyco-optimized trastuzumab-GEX, a novel anti-HER2 monoclonal antibody with ADCC activity: A phase I clinical study in patients with HER2-positive tumors.
Hellmut Samonigg
Research Funding - Medical University of Graz
Sara De Dosso
No relevant relationships to disclose
Antonella Perotti
No relevant relationships to disclose
Walter Fiedler
No relevant relationships to disclose
Guenther Gastl
No relevant relationships to disclose
Bruno Dietrich
Employment or Leadership Position - Glycotope GmbH
Kelvin Eckert
Employment or Leadership Position - Glycotope GmbH
Hans Baumeister
Employment or Leadership Position - Glycotope GmbH
Stock Ownership - Glycotope GmbH
Marc Oliver Salzberg
Consultant or Advisory Role - Glycotope GmbH
Steffen Goletz
Employment or Leadership Position - Glycotope GmbH
Stock Ownership - Glycotope GmbH